Skip to main content Skip to search
+34 659 496 544

Terapias Dirigidas para la Oncología de Precisión

Publicaciones

2023

Macaya, I, Roman, M, Welch, C, Entrialgo-Cadierno, R, Salmon, M, Santos, A, Feliu, I, Kovalski, J, Lopez, I, Rodriguez-Remirez, M, Palomino-Echeverria, S, Lonfgren, SM, Ferrero, M, Calabuig, S, Ludwig, IA, Lara-Astiaso, D, Jantus-Lewintre, E, Guruceaga, E, Narayanan, S, Ponz-Sarvise, M, Pineda-Lucena, A, Lecanda, F, Ruggero, D, Khatri, P, Santamaria, E, Fernandez-Irigoyen, J, Ferrer, I, Paz-Ares, L, Drosten, M, Barbacid, M, Gil-Bazo, I, Vicent, S (2023).

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

NATURE COMMUNICATIONS. Article. 14(1).
[doi:10.1038/s41467-023-41828-z]
Marrugal, A, Ferrer, I, Quintanal-Villalonga, A, Ojeda, L, Pastor, MD, García-Lujan, R, Carnero, A, Paz-Ares, L, Molina-Pinelo, S (2023).

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

International Journal Of Molecular Sciences. Article. 24(18).
[doi:10.3390/ijms241813830]